Objectives: The interest in isolated tricuspid valve disease has rapidly increased recently. However, clinical trials and registry data are rare in the surgical literature. This study aimed to describe the early and long-term outcomes of a real-world experience in isolated tricuspid procedures comparing repair and replacement strategies.
Methods: The Surgical-Tricuspid study is a multicentre retrospective study that enrolled adult patients who had undergone isolated tricuspid valve surgery at 13 international sites. Propensity score-matched analysis was used to compare repair versus replacement.
Results: A cohort of 426 patients was enrolled [mean age: 55 (16) years; 56% female]. After matching, 175 comparable pairs were analysed. Preoperative left ventricular ejection fraction was 55(9) vs 56(9) (P = 0.8) while moderate-severe tricuspid regurgitation was present in 95% of cases. The 30-day mortality rate was 4.0% vs 8.0% in the repair and replacement groups, respectively (P = 0.115). The rates of re-exploration for bleeding (6.9% vs 13.1% P = 0.050), permanent pacemaker implantation (5.1% vs 12.0%; P = 0.022) and blood transfusion (46% vs 62%; P = 0.002) were higher in the replacement group. Cumulative survival rates at 3, 5 and 7 years in the repair group were 84 (3)%, 75 (4)% and 56 (9)% vs 71 (4)%, 66 (5)% and 58 (5)% in the replacement group (P = 0.001) while cumulative incidence for reoperation at 10 years did not differ between groups [repair 10 (1)% vs replacement 9 (1)%; P = 0.469].
Conclusions: The data from the Surgical-Tricuspid study reported a high risk for patients undergoing tricuspid surgery. Isolated valve repair offered reduced early and late mortality with no difference regarding reoperation rate when compared with replacement.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/ejcts/ezac230 | DOI Listing |
Eur Heart J Cardiovasc Imaging
January 2025
The Department of Cardiovascular Medicine, Mayo Clinic, Rochester MN.
Aims: Pulmonary regurgitation (PR) after reparative intervention for congenital heart disease has been studied extensively. However, the burden, distribution of causes, and outcome of PR in adults is unknown. The study aimed to evaluate the prevalence, types, and outcomes of moderate/severe PR in adults in the community setting.
View Article and Find Full Text PDFAnn Thorac Surg Short Rep
December 2024
Department of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan.
Background: The rate of permanent pacemaker implantation after tricuspid valve (TV) operation is thought to be high, with some studies quoting rates of 20% to 30%. We identified the rate of pacemaker implantation after TV operation at a high-volume regional reference center to better characterize the contemporary risk of pacemaker.
Methods: All adult patients without preexisting pacemakers undergoing TV operation from 2011 to 2022 were included.
Ann Thorac Surg Short Rep
September 2024
HCA Healthcare Research Institute, HCA Healthcare, Nashville, Tennessee.
Background: Current treatment guidelines for infective endocarditis focus on left-sided infective endocarditis. Because right-sided infective endocarditis has different presentations and outcomes, it is crucial to further delineate surgical outcomes for isolated tricuspid valve endocarditis (TVE).
Methods: This retrospective study reviewed 374 surgically treated patients with isolated TVE from January 2012 through April 2022 who underwent isolated tricuspid valve surgical procedures.
JTCVS Open
December 2024
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn.
Objectives: Robotic-assisted mitral valve repair (MVr) is a well-established procedure for management of degenerative mitral valve disease. Limited data regarding concomitant robotic-assisted tricuspid valve repair (TVr) is available. This review investigates prevalence and outcomes of concomitant robotic-assisted mitral and tricuspid valve repair.
View Article and Find Full Text PDFInt J Cardiol
January 2025
Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, Japan. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!